Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for ...

The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack) for the ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

While several subcutaneous alkaline medications are useful in palliating ... the clinical impression of compatibility was not confirmed in the laboratory. However, this reflects common practice in ...

In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

It wouldn't make much sense to prohibit people from shooting a threatened woodpecker while allowing its forest to be cut down ...